AstraZeneca (AZN) Stock Dips Following Mixed FDA Panel Verdicts on Cancer Treatments

Key Takeaways

• AstraZeneca’s breast cancer treatment camizestrant received a 6-3 rejection vote from FDA’s ODAC panel
• The company’s prostate cancer therapy Truqap earned a 7-1 favorable recommendation from a separate advisory committee
• Shares of AZN declined 1.13% to $185.25 during premarket hours
• Analysts at Morgan Stanley highlighted potential “regulatory overhang” concerns after the negative camizestrant vote
• The pharmaceutical giant maintains confidence in camizestrant’s clinical data despite advisory panel concerns

AstraZeneca received contrasting verdicts from Food and Drug Administration advisory committees Thursday, experiencing both approval support and rejection for two separate oncology treatments.

Shares slipped 1.13% in Friday’s premarket session to $185.25. The stock has retreated approximately 6.9% over the last 30 days, underperforming the S&P 500’s 9.9% gain during the identical timeframe.

AstraZeneca PLC, AZN

The Oncologic Drugs Advisory Committee (ODAC) of the FDA examined a pair of AstraZeneca cancer medications during the same session — delivering markedly divergent recommendations.

On the unfavorable end, committee members cast a 6-3 vote against camizestrant, an orally administered breast cancer medication intended for first-line treatment of HR-positive, HER2-negative advanced breast cancer patients carrying ESR1 mutations.

Panel members determined that camizestrant failed to demonstrate a “meaningful benefit” for patients whose condition hadn’t yet progressed while on existing therapies.

According to clinical data from the SERENA-6 trial, camizestrant demonstrated a 56% decrease in disease advancement or mortality. Treatment recipients experienced a median progression-free period of 16 months, versus 9.2 months among those receiving current standard therapy.

However, advisors expressed apprehension regarding the completeness of crucial secondary endpoints, such as overall survival metrics and time to second progression, during the interim data review.

A subsequent pre-scheduled analysis revealed a statistically significant PFS2 advantage — 25.7 months compared to 19.1 months — while overall survival data continued trending favorably toward camizestrant.

AstraZeneca expressed “disappointment” regarding the vote outcome while reaffirming confidence in its clinical evidence and the medication’s patient value proposition.

Wall Street Analysts Express Caution

Morgan Stanley research team, headed by Sarita Kapila, described the outcome as creating “regulatory overhang and a dent to investor sentiment.”

They acknowledged that regulatory approval remains within the realm of possibility, though the 6-3 voting split diminishes probability for the SERENA-6 indication. While the FDA maintains discretion independent of advisory recommendations, the agency historically aligns with panel guidance. A definitive regulatory determination is anticipated.

Positive Outcome for Prostate Cancer Treatment

The day brought encouraging developments as well. For prostate cancer treatment, ODAC members voted 7-1 supporting Truqap (capivasertib), administered alongside abiraterone and androgen deprivation therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer patients.

The favorable recommendation stemmed from Phase 3 CAPItello-281 study findings, demonstrating a 19% reduction in disease progression or death risk.

Median radiographic progression-free survival extended to 33.2 months among Truqap recipients, compared with 25.7 months in the comparison group.

Additional endpoints similarly favored the treatment combination, including postponed progression toward castration resistance and enhanced PSA marker levels.

The safety assessment aligned with established knowledge regarding these therapeutic agents, though Grade 3 or more severe adverse reactions occurred more frequently within the Truqap cohort. Overall survival information continues maturing but demonstrates favorable directional trends for the combination approach.

AZN shares remain essentially unchanged year-to-date, contrasting with the S&P 500’s 4.8% advance over the matching period.

The post AstraZeneca (AZN) Stock Dips Following Mixed FDA Panel Verdicts on Cancer Treatments appeared first on Blockonomi.